On November 26, Pfizer Investments Co., Ltd. and China Resources Pharmaceutical Commercial Group Co., Ltd. formally signed a strategic cooperation agreement. The two sides will jointly promote the commercial operation of four high-quality mature drugs for lung cancer and breast cancer — Arnoxin®, Aiboxin®, Farmaxin®, and Secrex® to expand patient accessibility.

Zhitongcaijing · 11/26 12:33
On November 26, Pfizer Investments Co., Ltd. and China Resources Pharmaceutical Commercial Group Co., Ltd. formally signed a strategic cooperation agreement. The two sides will jointly promote the commercial operation of four high-quality mature drugs for lung cancer and breast cancer — Arnoxin®, Aiboxin®, Farmaxin®, and Secrex® to expand patient accessibility.